Implanting 3D Bioscaffolds in Rats Works to Trigger FVIII Production
Implanting bioscaffolds — 3D biological scaffolds made up of collagen and other molecules — carrying transformed liver cells into rats…
Articles by Steve Bryson, PhD
Patients on Prophylactics Maintain Pain Thresholds Over Year Study
Differences in sensory detection and pain thresholds were found in hemophilia patients taking prophylactics, compared to healthy individuals, and…
SerpinPC, for Hemophilia A and B, Safely Prevents Bleeds in Phase 2a Trial
SerpinPC, an experimental hemophilia therapy, at high dose safely reduced overall bleed rates by up to 88% and spontaneous…
Case Series: Plasma Exchange Can Help Reduce Bleeding in AHA
Therapeutic plasma exchange (TPE) was found to reduce bleeding and ease disease symptoms in six people with acquired hemophilia…
FDA Puts Hold on SIG-001 Phase 1/2 Trial for Hemophilia A
The U.S. Food and Drug Administration (FDA) has placed a clinical hold on Sigilon Therapeutics’ Phase 1/2 study evaluating…
Investigational Gene Therapy Increased FIX Production
Optimization of investigational hemophilia B gene therapy led to more than 25 times…
Gene Therapy Roctavian Prevents Bleeds Over 5 Years, Data Show
The investigational gene therapy Roctavian continues to effectively and safely prevent bleeding episodes and the need for clotting factor…
First Patient Dosed in Open-label Trial of MarzAA
The first participant has been dosed in a Phase 1/2 clinical trial evaluating marzeptacog alfa…
Data Show Potential of Roctavian Gene Therapy for Hemophilia A
Gene constructs making up Roctavian, an investigational gene therapy for hemophilia…
Catalyst’s FIX Gene Therapy More Effective Than Padua in Early Study
An investigational gene therapy for hemophilia B, called CB 2679d-GT, increased factor IX…